08:00 , Nov 3, 2008 |  BioCentury  |  Finance

Ebb & Flow

Cardiovascular and pulmonary company Dyax (NASDAQ: DYAX) has found a bevy of ways to bring in cash this year, despite the poor funding environment. Its latest move was to set up a $50 million committed...
07:00 , Apr 24, 2006 |  BioCentury  |  Finance

Ebb & Flow

Acqua Capital marked its return to biotech investing last week with its largest ever financing facility - a $200 million equity line for cardiovascular play CV Therapeutics (CVTX). Although the deal was with a longtime...
07:00 , Apr 3, 2006 |  BioCentury  |  Finance

2nd Quarter Stock Preview: Small winners add up

Buysiders have been predicting that 2006 would see a narrowing of the gap between the performance of big and small biotechs. Thus far, that assumption has panned out, with the smaller plays gaining ground on...
07:00 , Aug 7, 2003 |  BC Extra  |  Financial News

CVTX files shelf

Cardiovascular company CV Therapeutics (CVTX) filed a shelf registration covering the sale of up to $111.3 million of common stock. The filing relates to the $100 million equity line of credit the company entered into...
08:00 , Mar 24, 2003 |  BC Extra  |  Financial News

CV Therapeutics raises $11.8 million

Cardiovascular company CVTX raised $11.8 million through the sale of 700,000 shares to Acqua Wellington North American Equities Fund at $16.91 per share. The shares were sold under a 2000 equity-stock purchase plan, and the...
08:00 , Feb 10, 2003 |  BioCentury  |  Finance

The sound of silence

The government's proposed overhaul of how Wall Street does business aims to erase the role of sellside analysts in the financing process, imposing new worries on a biotech sector already littered with microcap companies that...
07:00 , Aug 8, 2002 |  BC Extra  |  Financial News

CV Therapeutics raises $12.5 million

CVTX raised $12.5 million through the sale of 561,000 shares at an average price of $22.28 to Acqua Wellington North American Equities Fund under a 2000 equity-stock purchase plan. CVTX, which is developing therapeutics for...
07:00 , Jul 1, 2002 |  BioCentury  |  Finance

Many fall under the radar

2Q Financial Markets Review Many fall under the radar A corollary to shrinking market caps is a stock price that can't be hyped. Wall Street analysts and brokers typically can't recommend stocks below $5 per share, and...
07:00 , Jul 1, 2002 |  BioCentury  |  Finance

2Q Financial Markets Review: Hard decisions loom

The biotech selloff has contracted multiples for profitable companies and lowered technology values for development stage companies. While the former will survive - and even trade up if a multiple expansion occurs - there are...
07:00 , Jun 17, 2002 |  BioCentury  |  Finance

Biotech's blue shift

The biotech downdraft is having an ugly side effect outside of losing investors a lot of money: It's drastically reducing the number of "investable" biotech companies. Wall Street typically considers any company with a market...